SPY313.78-3.27 -1.03%
DIA259.04-3.96 -1.51%
IXIC10,343.89-89.76 -0.86%

Credit Suisse Downgrades Intercept Pharmaceuticals to Neutral, Lowers Price Target to $59

Credit Suisse analyst Tiago Fauth downgrades Intercept Pharmaceuticals (NASDAQ:ICPT) from Outperform to Neutral and lowers the price target from $137 to $59.

Benzinga · -
Credit Suisse analyst Tiago Fauth downgrades Intercept Pharmaceuticals (NASDAQ: ICPT) from Outperform to Neutral and lowers the price target from $137 to $59.